The effectiveness of levocetirizine in comparison with loratadine in treatment of allergic rhinitis-a meta-analysis

Allergology International

Volumn 60, Issue 4, 2011, Pages 541-546

  Mösges, Ralph ^a   König, Volker ^a   Köberlein, Juliane ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF WUPPERTAL   (Germany)

Author keywords

Allergic rhinitis; Double blinded placebo controlled study; Levocetirizine; Loratadine; Meta analysis

Indexed keywords

LEVOCETIRIZINE; LORATADINE; PLACEBO;

ALLERGIC RHINITIS; ARTICLE; COMPARATIVE STUDY; DRUG EFFICACY; HUMAN; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 83455257990     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.10-OA-0300     Document Type: Article

References (17)

1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:147-334.
2. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63 (Suppl 86):8-160.
3. Simons FE. Advances in H1-antihistamines. N Engl J Med 2004;351:2203-17.
4. Bachert C, Bousquet J, Canonica GW et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004;114:838-44.
5. Guadano EM, Serra-Batlles J, Meseguer J et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy 2004;59:766-71.
6. Bousquet J, Demarteau N, Mullol J et al. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy 2005;60:788-94.
7. Patou J, De Smedt H, van Cauwenberge P, Bachert C. Pathophysiology of nasal obstruction and meta-analysis of early and late effects of levocetirizine. Clin Exp Allergy 2006;36:972-81.
8. Walter Canonica G, Bousquet J, Van Hammee G et al. Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respir Med 2006;100:1706-15.
9. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
10. Ciebiada M, Gorska-Ciebiada M, DuBuske LM, Gorski P. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol 2006;97:664-71.
11. Lee CF, Sun HL, Lu KH, Ku MS, Lue KH. The comparison of cetirizine, levocetirizine and placebo for the treatment of childhood perennial allergic rhinitis. Pediatr Allergy Immunol 2009;20:493-9.
12. Anolik R. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008; 100:264-71.
13. Hampel F Jr, Howland W 3rd, Van Bavel J, Ratner P. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol 2004;14:56-63.
14. Ratner P, Hampel F Jr, Van Bavel J, Howland W 3rd. Efficacy and safety of ebastine 20 mg compared to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled study. Int Arch Allergy Immunol 2004;133:371-9.
15. van Adelsberg J, Philip G, Pedinoff AJ et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003;58:1268-76.
16. Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol 2004;92:294-303; quiz-5, 55.
17. Phan H, Moeller ML, Nahata MC. Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Drugs 2009;69:2541-76.